Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15
ConclusionHealthy donor-derived DNTs can target NSCLC in vitro and in vivo. DNTs recognize tumors via innate receptors which can be up-regulated by IL-15. DNTs have the potential to be used as a novel adoptive cell therapy for lung cancer either alone or in combination with IL-15.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Leukemia | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer